Blood Pressure News and Research

RSS

Blood Pressure is the force of circulating blood on the walls of the arteries. Blood pressure is taken using two measurements: systolic (measured when the heart beats, when blood pressure is at its highest) and diastolic (measured between heart beats, when blood pressure is at its lowest). Blood pressure is written with the systolic blood pressure first, followed by the diastolic blood pressure (for example 120/80).

Increased mortality rates in Bangladesh is associated with arsenic exposure, study finds

Between 33 and 77 million people in Bangladesh have been exposed to arsenic in the drinking water-a catastrophe that the World Health Organization has called "the largest mass poisoning in history." A new study published in the current issue of the medical journal The Lancet provides the most complete and detailed picture to date of the high mortality rates associated with this exposure, which began with the widespread installation of tube wells throughout the country 30 years ago-a measure intended to control water-bourne diseases.

24 Jun 2010

Ingredients for an "anti-aging potion"

Aging without getting old? It's largely possible, according to the June issue of Mayo Clinic Health Letter.

24 Jun 2010

NIH to invest $25M over five years for international collaboration on genetic research in Africa

The NIH on Tuesday announced a partnership with Wellcome Trust and the African Society for Human Genetics that will enable African researchers to "use the latest genetic and clinical technology to study common health problems, such as cardiovascular disease, cancer and other diseases," VOA News reports (DeCapua, 6/22).

24 Jun 2010

Spherix to explore triglycerides for D-tagatose therapy

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.

24 Jun 2010

Carvedilol drug may lessen degenerative impact of Alzheimer's disease: Researchers

Researchers at Mount Sinai School of Medicine have found that the drug carvedilol, currently prescribed for the treatment of hypertension, may lessen the degenerative impact of Alzheimer's disease and promote healthy memory functions. The new findings are published in two studies in the current issues of Neurobiology of Aging and the Journal of Alzheimer's Disease.

24 Jun 2010

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).

23 Jun 2010

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease.

23 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.

23 Jun 2010

Metabolic syndrome can negatively affect donor's kidney function outcome, study finds

People who donate one of their kidneys experience faster deterioration of their other kidney if they have the metabolic syndrome at the time of donation, a new study finds. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Cytochrome P450 plays important role in management of high blood pressure: Researchers

Researchers have found that increasing certain proteins in the blood vessels of mice, relaxed the vessels, lowering the animal's blood pressure. The study provides new avenues for research that may lead to new treatments for hypertension.

22 Jun 2010

Novel MC4R agonist exhibits potential as new treatment for obesity, diabetes

Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, today announced a study of obese primates treated with RM-493 showing a reversal of obesity and insulin resistance, and improvement in both heart rate and blood pressure. RM-493 is a novel peptide agonist targeting the melanocortin 4 receptor (MC4R) that is a clinical candidate for the treatment of obesity and diabetes.

22 Jun 2010

SYMPLICITY HTN-1 study: RDN treatment significantly reduces blood pressure

Long-term data presented today from Ardian's SYMPLICITY HTN-1 study demonstrate that the significant reductions in blood pressure achieved using Renal Denervation treatment are sustained through 24 months. The data were presented at the late breaking trials session of the European Society of Hypertension Annual Scientific meeting in Oslo, Norway.

22 Jun 2010

Four-year clinical study results show sustained effect that Rheos System has on reducing hypertension

CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.

22 Jun 2010

Women who experience early menopause may have cardiovascular disease later in life: Study

Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

Palatin Technologies, Inc. today announced results of preclinical studies in respiratory tissue with PL-3994. In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans.

21 Jun 2010

Spark Together for Health Kids program promotes access to physical activity, healthy food

A new survey by the Heart and Stroke Foundation of Ontario found the majority of kids in the Greater Toronto Area (GTA) will be missing out on physical activity this summer, as parents scramble to find child care solutions once school is out.

21 Jun 2010

Consumers can now access high quality health and medical information on Internet using Medgateway.com

With the vast amount of medical information on the Internet, consumers can spend long hours looking for health and medical information. Consumers can access reliable, high quality health and medical information on the Internet using Medgateway.com. Medgateway provides links to numerous health and medical web sites.

21 Jun 2010

Magic Power Coffee can dangerously lower blood pressure, warns FDA

The U.S. Food and Drug Administration is warning consumers that Magic Power Coffee, an instant coffee product marketed as a dietary supplement for sexual enhancement, contains an active drug ingredient that can dangerously lower blood pressure.

21 Jun 2010

Metabolically healthy obese people appear to have protection against cardiovascular disease: Study

Obese people without metabolic risk factors for diabetes and heart disease, such as high blood pressure and cholesterol, do not have the elevated cardiovascular risk typical of obesity, but they represent only a small percentage of the obese population, according to a long-term study. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego

21 Jun 2010

Blood Pressure News and Research

Further Reading

Increased mortality rates in Bangladesh is associated with arsenic exposure, study finds

Ingredients for an "anti-aging potion"

NIH to invest $25M over five years for international collaboration on genetic research in Africa

Spherix to explore triglycerides for D-tagatose therapy

Carvedilol drug may lessen degenerative impact of Alzheimer's disease: Researchers

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Metabolic syndrome can negatively affect donor's kidney function outcome, study finds

Cytochrome P450 plays important role in management of high blood pressure: Researchers

Novel MC4R agonist exhibits potential as new treatment for obesity, diabetes

SYMPLICITY HTN-1 study: RDN treatment significantly reduces blood pressure

Four-year clinical study results show sustained effect that Rheos System has on reducing hypertension

Women who experience early menopause may have cardiovascular disease later in life: Study

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

Spark Together for Health Kids program promotes access to physical activity, healthy food

Consumers can now access high quality health and medical information on Internet using Medgateway.com

Magic Power Coffee can dangerously lower blood pressure, warns FDA

Metabolically healthy obese people appear to have protection against cardiovascular disease: Study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News